NCT02917993 2026-02-09An Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerIncyte CorporationPhase 1/2 Completed59 enrolled
NCT02355431 2019-03-08Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsIncyte CorporationPhase 2 Withdrawn
NCT02257619 2018-01-25Study of INCB039110 in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerIncyte CorporationPhase 2 Terminated9 enrolled